Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries

B. Corbacho (), M. Drummond, Rita Santos, E. Jones, J. M. Borràs, J. Mestre-Ferrandiz, J. Espín, N. Henry and Andrea Prat
Additional contact information
B. Corbacho: University of York
M. Drummond: University of York
E. Jones: Pope Woodhead
J. M. Borràs: Universidad de Barcelona
J. Mestre-Ferrandiz: Independent Economics Consultant
J. Espín: Investigación Biosanitaria (ibs.GRANADA)
N. Henry: CIBER de Epidemiología y Salud Pública (CIBERESP)

The European Journal of Health Economics, 2020, vol. 21, issue 4, No 10, 634 pages

Abstract: Abstract Objectives A centralised approach to health technology assessment (HTA) may facilitate optimal use of HTA resources. A regional approach may increase the chances of local implementation of recommendations. This study aimed to compare assessment procedures in England (centralised HTA approach) with Spain (regional HTA approach) discussing key challenges and opportunities from both approaches. Methods We compared technology assessments of anticancer medicines in the two jurisdictions from 2008 to 2015. To assess the implementation of HTA recommendations, we assessed trends in medicine usage using regression methods. We used IQVIA data, from 2011 to 2016, for a sample of 11 medicines. We used CatSalut data from Catalonia to assess the implementation of local recommendations. Results In England, 66 assessments were undertaken by the National Institute for Health and Care Excellence (NICE), using a standardised methodology. In Spain, there were 79 reports undertaken by a range of bodies using a shared process and coordinated through the GENESIS collaboration; the assessment methods used varied substantially. Overall, the recommendations in the two jurisdictions were similar. Regression analyses indicate that where there is a positive recommendation by HTA bodies, the usage of the medicine responds most strongly (p

Keywords: HTA methods; Decision making; Cost-effectiveness; Cancer; I15; I18 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s10198-020-01160-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:4:d:10.1007_s10198-020-01160-5

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-020-01160-5

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().